Format

Send to

Choose Destination
Vaccine. 2016 Apr 19;34(18):2062-5. doi: 10.1016/j.vaccine.2016.02.043. Epub 2016 Feb 23.

Vaccine effectiveness of PCV13 in a 3+1 vaccination schedule.

Author information

1
Division of Epidemiology, Institute of Social Pediatrics and Adolescent Medicine, Ludwig-Maximilians-University Munich, Munich, Germany. Electronic address: Raphael.Weinberger@med.uni-muenchen.de.
2
National Reference Centre for Streptococci, Institute of Medical Microbiology, University Hospital RWTH Aachen, Aachen, Germany.
3
Division of Epidemiology, Institute of Social Pediatrics and Adolescent Medicine, Ludwig-Maximilians-University Munich, Munich, Germany.

Abstract

OBJECTIVE:

To assess the vaccine effectiveness (VE) of PCV13 for invasive pneumococcal disease (IPD) regarding the extra six serotypes with a 3+1 schedule in Germany.

METHODS:

Active surveillance for IPD in children <16 years eligible for PCV13 vaccination. We used the Broome method and logistic regression to estimate VE.

RESULTS:

Data on 164/304 reported IPD cases were informative and met the inclusion criteria. VE for the extra six serotypes was 88% [95% confidence interval (CI): 73; 95] and 83% [56; 94] for at least one and for at least two doses respectively. VE for the complete 3+1 vaccination schedule was not conclusive because of a wide 95% CI. For serotype 3 VE appeared to be zero with an even wider 95% CI.

CONCLUSION:

PCV13 VE against the extra six serotypes with the 3+1 schedule in Germany was only marginally higher compared to previously published data for the 2+1 schedule.

KEYWORDS:

3+1 Vaccination schedule; Germany; Invasive pneumococcal disease; Pneumococcal conjugate vaccination; Vaccine effectiveness PCV13

PMID:
26920471
DOI:
10.1016/j.vaccine.2016.02.043
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center